Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population-Reference-Cited by-同舟云学术

Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population

Published:2019-10-18 Issue:1 Volume:23 Page:54-63
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Wu Bingcao¹,Li Sophia S.¹,Song Ji¹,Pericone Christopher D.¹,Behl Ajay S.¹,Dawson Nancy A.²

Affiliation:

1. Janssen Scientific Affairs, Titusville, NJ, USA;

2. Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1678171

Reference29 articles.

1. Key Statistics for Prostate Cancer. American Cancer Society; 2019 [accessed 2019 Mar 26]. Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

2. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Version 4.2018. National Comprehensive Cancer Network; 2018 Aug 15 [accessed 2018 Oct 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

4. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer

5. Recent Advances in Prostate Cancer Treatment and Drug Discovery

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer;Annals of Internal Medicine;2024-07

2. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States;Journal of Managed Care & Specialty Pharmacy;2024-07

3. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States;Journal of Medical Economics;2024-03-11

4. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation;Journal of Medical Economics;2024-02-02

5. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data;Clinical Genitourinary Cancer;2023-10